Menu
Back to Journals » OncoTargets and Therapy » Volume 12
RETRACTED ARTICLE: Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line
Authors Xu X, Yan Y , Xun Q, Shi J, Kong X, Wu J, Zhou H
Received 9 November 2018
Accepted for publication 20 January 2019
Published 14 February 2019 Volume 2019:12 Pages 1215—1223
DOI https://doi.org/10.2147/OTT.S194064
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr XuYu Yang
This paper has been retracted.
Xu X, Yan Y, Xun Q, et al. Onco Targets Ther. 2019;12:1215-1223.
We, the Editor and Publisher of the journal OncoTargets and Therapy have retracted the published article.
Following publication of the article, the authors raised concerns about the duplication of images from Figure 2. Specifically,
- The images for Figure 2D, siVEGF and siANG, have been duplicated.
The corresponding author was cooperative and responded to our queries but was unable to provide a satisfactory explanation for how the images came to be duplicated or provide satisfactory original data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the Publisher and Editor requested to retract the article and the corresponding author was notified of this.
We have been informed in our decision-making by our editorial policies and COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.